AU7241094A - Bispecific antigen-binding molecules - Google Patents

Bispecific antigen-binding molecules

Info

Publication number
AU7241094A
AU7241094A AU72410/94A AU7241094A AU7241094A AU 7241094 A AU7241094 A AU 7241094A AU 72410/94 A AU72410/94 A AU 72410/94A AU 7241094 A AU7241094 A AU 7241094A AU 7241094 A AU7241094 A AU 7241094A
Authority
AU
Australia
Prior art keywords
antigen
fork
cell
antigens
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU72410/94A
Other languages
English (en)
Inventor
Sylvia T Hsieh-Ma
David B. Ring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU7241094A publication Critical patent/AU7241094A/en
Priority to AU81878/98A priority Critical patent/AU8187898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AU72410/94A 1993-04-09 1994-03-21 Bispecific antigen-binding molecules Abandoned AU7241094A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU81878/98A AU8187898A (en) 1993-04-09 1998-08-25 Bispecific antigen-binding molecules

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4596993A 1993-04-09 1993-04-09
US045969 1993-04-09
US16398893A 1993-12-07 1993-12-07
PCT/US1994/003171 WO1994024163A2 (en) 1993-04-09 1994-03-21 Bispecific antigen-binding molecules
US163988 2002-06-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU81878/98A Division AU8187898A (en) 1993-04-09 1998-08-25 Bispecific antigen-binding molecules

Publications (1)

Publication Number Publication Date
AU7241094A true AU7241094A (en) 1994-11-08

Family

ID=26723417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72410/94A Abandoned AU7241094A (en) 1993-04-09 1994-03-21 Bispecific antigen-binding molecules

Country Status (5)

Country Link
EP (1) EP0804487A2 (de)
JP (1) JPH08510116A (de)
AU (1) AU7241094A (de)
CA (1) CA2160224A1 (de)
WO (1) WO1994024163A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531348A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2011115062A1 (ja) * 2010-03-15 2011-09-22 国立大学法人 岡山大学 抗腫瘍作用補助剤
CA3233584A1 (en) 2013-12-27 2015-07-02 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
TW202216788A (zh) * 2020-06-26 2022-05-01 日商協和麒麟股份有限公司 與GPC3及TfR結合之雙特異性抗體

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies

Also Published As

Publication number Publication date
WO1994024163A3 (en) 1994-12-08
WO1994024163A2 (en) 1994-10-27
EP0804487A2 (de) 1997-11-05
CA2160224A1 (en) 1994-10-27
JPH08510116A (ja) 1996-10-29

Similar Documents

Publication Publication Date Title
US5705614A (en) Methods of producing antigen forks
JP3589459B2 (ja) 生物応答調節物質の新規な抗体運送システム
US9914777B2 (en) Human CD3 binding antibody
CN109320612B (zh) 抗her2抗体及其缀合物
EP0557300B1 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
JP3822653B2 (ja) リンパ球抗原ｃｄ２および腫瘍抗原を認識する二特異性トリガー分子
US5470571A (en) Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
US8759494B2 (en) Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses
US5801227A (en) Antibodies to CD40
KR0152272B1 (ko) 암 진단 및 치료용 면역접합체
KR101048894B1 (ko) 항-인간 테나신 단클론 항체
US20070249529A1 (en) Compositions Comprising Polypeptides
CN107106683A (zh) 含靶向与效应组件的分子构建体
JPH10511085A (ja) 二重特異性抗体を用いる免疫応答を促進する方法
CN109195988B (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
HUT53153A (en) Process for producing bispecific monoclonal antibody
JP3340127B2 (ja) 異常増殖性疾患措置のための抗体接合体
JP2002502621A (ja) 乳腫瘍を伴うムチンに対する特異性のある抗体、その生産方法及び使用方法
WO1986007089A1 (en) Murine hybridoma lym-2 and diagnostic antibody produced thereby
AU7241094A (en) Bispecific antigen-binding molecules
JP2000509015A (ja) Ｔ細胞及びｂ細胞リンパ腫及び白血病の治療のためのｃｄ４８に対する抗体の使用
EP0441917B1 (de) Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern
EP0381763B1 (de) Mit toxin modifizierter antikörper
US20060177454A1 (en) Method of promoting an immune response with a bispecific antibody
WO2019013674A1 (ru) Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей